NO314935B1 - 2-{3-[4-(2-t-Butyl-6-trifluormetyl-4-pyrimidinyl)-1- piperazinyl]propyltio}-4-pyrimidinol-fumarat - Google Patents

2-{3-[4-(2-t-Butyl-6-trifluormetyl-4-pyrimidinyl)-1- piperazinyl]propyltio}-4-pyrimidinol-fumarat Download PDF

Info

Publication number
NO314935B1
NO314935B1 NO20000665A NO20000665A NO314935B1 NO 314935 B1 NO314935 B1 NO 314935B1 NO 20000665 A NO20000665 A NO 20000665A NO 20000665 A NO20000665 A NO 20000665A NO 314935 B1 NO314935 B1 NO 314935B1
Authority
NO
Norway
Prior art keywords
butyl
piperazinyl
trifluoromethyl
fumarate
pyrimidinol
Prior art date
Application number
NO20000665A
Other languages
English (en)
Norwegian (no)
Other versions
NO20000665L (no
NO20000665D0 (no
Inventor
Stefan Blank
Dorothea Starck
Hans-Joerg Treiber
Stefan Koser
Bernd Schaefer
Marco Thyes
Thomas Hoeger
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of NO20000665L publication Critical patent/NO20000665L/no
Publication of NO20000665D0 publication Critical patent/NO20000665D0/no
Publication of NO314935B1 publication Critical patent/NO314935B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20000665A 1997-08-14 2000-02-10 2-{3-[4-(2-t-Butyl-6-trifluormetyl-4-pyrimidinyl)-1- piperazinyl]propyltio}-4-pyrimidinol-fumarat NO314935B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19735410A DE19735410A1 (de) 1997-08-14 1997-08-14 2-{3-[4-(2-t-Butyl-6-trifluormethylpyrimidin-4-yl)piperazin-1-yl]propylmercapto}pyrimidin-4-ol-fumarat
PCT/EP1998/005178 WO1999009015A1 (fr) 1997-08-14 1998-08-14 Fumarate de 2-{3-(4-(2-t-butyl-6- trifluoromethylpyrimidin-4-yl) piperazin-1-yl] propylmercapto} pyrimidin-4-ol

Publications (3)

Publication Number Publication Date
NO20000665L NO20000665L (no) 2000-02-10
NO20000665D0 NO20000665D0 (no) 2000-02-10
NO314935B1 true NO314935B1 (no) 2003-06-16

Family

ID=7839072

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20000665A NO314935B1 (no) 1997-08-14 2000-02-10 2-{3-[4-(2-t-Butyl-6-trifluormetyl-4-pyrimidinyl)-1- piperazinyl]propyltio}-4-pyrimidinol-fumarat

Country Status (25)

Country Link
US (1) US20010020022A1 (fr)
EP (2) EP1003728B1 (fr)
JP (1) JP4444492B2 (fr)
KR (1) KR100571945B1 (fr)
CN (1) CN1267286A (fr)
AR (1) AR016605A1 (fr)
AT (1) ATE525362T1 (fr)
AU (1) AU749575B2 (fr)
BG (1) BG104122A (fr)
BR (1) BR9811177A (fr)
CA (1) CA2301297A1 (fr)
CO (1) CO4960663A1 (fr)
DE (1) DE19735410A1 (fr)
ES (1) ES2374156T3 (fr)
HU (1) HUP0003710A3 (fr)
ID (1) ID24639A (fr)
IL (1) IL134246A (fr)
NO (1) NO314935B1 (fr)
NZ (1) NZ502675A (fr)
PL (1) PL201927B1 (fr)
SK (1) SK1182000A3 (fr)
TR (1) TR200000406T2 (fr)
TW (1) TW467912B (fr)
WO (1) WO1999009015A1 (fr)
ZA (1) ZA987239B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE402704T1 (de) * 2000-03-27 2008-08-15 Abbott Gmbh & Co Kg Dopamin-d3-rezeptor-liganden zur behandlung von sucht
DE10101307A1 (de) * 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
DE102004027358A1 (de) 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyrimidinverbindungen und ihre Verwendung
ES2340941T3 (es) * 2004-08-09 2010-06-11 ABBOTT GMBH & CO. KG Compuestos de 4-piperazinil-pirimidina adecuados para tretar trastornos que responden a modulacion del receptor d 3 de dopamina.
CN102887860B (zh) * 2012-09-29 2015-07-01 上海泰坦科技有限公司 4-氯-6-三氟甲基嘧啶类化合物的制备方法
US9598387B2 (en) 2012-10-11 2017-03-21 Southern Research Institute Urea and amide derivatives of aminoalkylpiperazines and use thereof
US9376396B2 (en) 2012-10-22 2016-06-28 AbbVie Deutschland GmbH & Co. KG Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4425143A1 (de) * 1994-07-15 1996-01-18 Basf Ag Substituierte Pyrimidinverbindungen und deren Verwendung

Also Published As

Publication number Publication date
EP2272833A1 (fr) 2011-01-12
AU9342698A (en) 1999-03-08
PL338603A1 (en) 2000-11-06
HUP0003710A3 (en) 2002-01-28
TR200000406T2 (tr) 2000-05-22
PL201927B1 (pl) 2009-05-29
JP4444492B2 (ja) 2010-03-31
KR20010022833A (ko) 2001-03-26
ES2374156T3 (es) 2012-02-14
WO1999009015A1 (fr) 1999-02-25
CO4960663A1 (es) 2000-09-25
IL134246A (en) 2002-11-10
CN1267286A (zh) 2000-09-20
ATE525362T1 (de) 2011-10-15
AR016605A1 (es) 2001-07-25
US20010020022A1 (en) 2001-09-06
SK1182000A3 (en) 2000-09-12
ID24639A (id) 2000-07-27
CA2301297A1 (fr) 1999-02-25
EP1003728B1 (fr) 2011-09-21
ZA987239B (en) 2000-02-14
NO20000665L (no) 2000-02-10
IL134246A0 (en) 2001-04-30
BG104122A (en) 2000-11-30
BR9811177A (pt) 2000-07-25
JP2001515070A (ja) 2001-09-18
AU749575B2 (en) 2002-06-27
HUP0003710A2 (hu) 2001-10-28
DE19735410A1 (de) 1999-02-18
KR100571945B1 (ko) 2006-04-18
EP1003728A1 (fr) 2000-05-31
NO20000665D0 (no) 2000-02-10
NZ502675A (en) 2001-06-29
TW467912B (en) 2001-12-11

Similar Documents

Publication Publication Date Title
JP5425057B2 (ja) Ｈｓｐ９０阻害剤としてのキナゾリン−オキシム誘導体
TWI345562B (en) Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
NO325321B1 (no) Piperazinylpyrazinforbindelser, preparat, fremgangsmate for fremstilling samt anvendelse av slike
WO1997019065A1 (fr) 2-anilinopyrimidines substituees utiles en tant qu'inhibiteurs de proteine kinase
NO312030B1 (no) Substituerte pyrimidinforbindelser, anvendelse og fremstilling derav, samt farmasöytisk middel
KR20060009900A (ko) 피페리디닐- 및 피페라지닐-알킬 카르바메이트 유도체,그의 제조 방법 및 그의 치료 용도
NO316753B1 (no) Substituerte aza- og diazacykloheptan og -cyklooktan-forbindelser og deres anvendelser, samt farmasoytiske blandinger inneholdende slike forbindelser
TW201625568A (zh) 作爲類香草素受體之配位體ｉｉ之經取代以噁唑及噻唑爲主之甲醯胺及脲衍生物
WO2018183712A1 (fr) Composés de pyrrolo[1,2-b]pyridazine et compositions utiles pour traiter des troubles liés à kit et pdgfr
US3944551A (en) N-Coumaranyl and chromanyl -methyl-or sulfur analogs thereof-N'- thiazolyl piperazines
JPS61155358A (ja) ジアリール酪酸誘導体
NO314935B1 (no) 2-{3-[4-(2-t-Butyl-6-trifluormetyl-4-pyrimidinyl)-1- piperazinyl]propyltio}-4-pyrimidinol-fumarat
KR20010015787A (ko) 테트라히드로피리도피리미디논의 제3 위치 치환 유도체,그의 제조 방법 및 용도
DK156722B (da) Analogifremgangsmaade til fremstilling af 2-piperazinopyrimidinderivater
JPH05202054A (ja) アミノメチル置換２，３−ジヒドロピラノ〔２，３−ｂ〕ピリジン類
GB2171997A (en) 4-Amino-6,7-dimethoxy-2-Piperazin-1-ylquinazoline derivatives
US6486162B2 (en) 2-{3-[4-(2-t-butyl-6-trifluoromethyl-4-pyrimidinyl)-1- piperazinyl] propylthio}-4-pyrimidinol fumarate
WO1995019345A1 (fr) Derive du diazacycloalcanealkylsufonamide
MXPA00001161A (en) 2-{3-[4-(2-T-BUTYL-6- TRIFLUOROMETHYLPYRIDIN-4-YL) PIPERAZIN-1-YL]PROPYLMERCAPTO}PYRIMIDIN-4-OL-FUMARATE
CZ2000450A3 (cs) Sůl 2-[3-/4-(2-terc.-butyl-6-trifluormethyl-4- pyrimidinyl)-1-piperazinyl/propylthio]-4- pyrimidínolu s kyselinou fumarovou
WO2025003343A1 (fr) Modulateurs de kv7
NO884332L (no) Cellebeskyttende stoffer.
JPS61148144A (ja) フエニル酪酸誘導体
JP2005320273A (ja) ５−アミノピリミジン化合物